Adalimumab-Aacf(Cf) Pen (2 Pk) (Adalimumab-Aacf) Patent Expiration, LOE Window & CMS Spending

Adalimumab-Aacf(Cf) Pen (2 Pk) (Adalimumab-Aacf) by Fresenius Kabi: Off-Patent Genericized (AB Competition), 0 AB generics, $1.0M 2024 CMS Part D & Medicaid spend, and $2,697 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.0M
2024 Medicare Part D Spend$819K
2024 Medicaid Spend$203K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,697 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.